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INTRODUCTION
Acute (presumed bacterial) rhinosinusitis (ARS) is one of the 
most common disease for prescribing antibiotics in general prac-
tice (1). Although antibiotic prescription should be based on stan-
dard bacteriologic studies, this takes additional time causing de-
lay in treatment and clinicians are often confronted to prescribe 
antibiotics empirically. The most common bacterial pathogens 
involved in ARS are Streptococcus pneumonia, Haemophilus 
influenza, and Moraxella catarralis (1, 2). Empirically chosen 
antibiotics should target these organisms and loco-regional bac-
terial resistance pattern, disease severity, progression of the dis-
ease and recent antibiotic exposure should be considered.
  The goal of antibiotic therapy is to eradicate the bacterial path-
ogens to alleviate symptoms, prevent complications and finally 
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aid in recovering normal sinus physiology. 
  Cefcapene pivoxil (CP) is a broad spectrum oral ester cepha-
losporin that has been developed in Japan (3). A recent study 
showed that 5-day treatment with oral CP was safe and effective 
for treating group A β-hemolytic streptococcus infection resulting 
in microbiological and clinical improvement which were equal 
to a 10-day treatment with oral amoxicillin (3). In clinical setting, 
concerning about the potential impact of antibiotics on bacterial 
resistance, selection of antibiotics is the question pressing for se-
rious consideration. 
  In Korea, many physicians tend to prescribe the amoxicillin/
clavulanate or cephalosporin as a first line therapy instead of 
amoxicillin due to bacterial resistance. To our knowledge, there 
is no data comparing the clinical efficacy of CP and amoxicillin-
clavulanate (AMC) for the treatment of ARS. Therefore, we de-
signed a randomized, open labeled, double-blinded study to 
compare CP with AMC in terms of clinical efficacy and safety.
MATERIALS AND METHODS
Study design
A randomized, open labeled, double-blinded study was designed. 
Patients were randomly assigned to either CP or AMC groups 
using the table of random sampling numbers: the former received 
150 mg tablet three times daily (450 mg/day) and the latter 625 
mg tablet three times daily (4:1 form of AMC, Amoxicillin 1,500 
mg/day) for 14 days. Usually, 100-150 mg of CP three times a 
day is prescribed for these cases in our institution. So, we ad-
ministrated 150 mg of CP three times a day. The patients were 
blinded to treatment which was allocated by a randomization 
schedule. Use of antibiotics other than the study drugs was pro-
hibited throughout the study. However, there was no restriction 
to other symptomatic medications including antihistamines, de-
congestants, and mucolytics. Any patients who had hypersensi-
tivity to penicillin, cephalosporin and beta-lactam lineage anti-
biotics or had been on antibiotics 2 weeks before enrollment 
were excluded from this study. Patients who experienced orbital 
cellulitis or intracranial extension of the infection or who were 
required to be hospitalized are considered to have severe dis-
ease and are excluded.
  The study was approved by the institutional review board of 
Seoul National University Hospital. All patients were provided 
with written informed consent before initiation of study.
Patient selection
Between June 2007 and January 2010, patients over 15 years of 
age with a clinical diagnosis of ARS were recruited from the out-
patient clinic of Seoul National University Hospital, Seoul, Ko-
rea. The diagnosis of ARS (presumed bacterial) was made based 
on the guidelines provided by the American Academy of Otolar-
yngology-Head and Neck Surgery (4). Diagnosis required symp-
toms consistent with ARS plus objective findings. 
  Patients with symptoms of ARS that showed the following 
patterns were included; symptoms present for at least 10 days 
and up to 28 days; patients with severe disease with presence of 
nasal purulence for 3-4 days with high fever; and patients whose 
symptoms initially regress but then worsen within the first 10 
days. Symptoms of ARS included at least 2 major symptoms or 
1 major plus 2 minor symptoms. Major symptoms consisted of 
facial pressure/pain, facial congestion, nasal obstruction, puru-
lent nasal discharge, post nasal drip, hyposmia/anosmia and fe-
ver, while minor symptoms included headache, mouth odor, fa-
tigue, tooth pain, cough and ear fullness or pain.
Clinical assessment
The patients’ symptoms were assessed using a scale from 0 to 3 
(0=absent, 1=improvement but remained, 2=same as before, 
3=aggravated). Nasal endoscopy and paranasal sinuses X-rays 
(Waters and Caldwell views) were also performed in every pa-
tient during the initial visit day for confirmation of the diagnosis 
and follow up images were performed to monitor progress and 
check effectiveness. Endoscopic examinations were performed 
on days 1, 7, and 14 and paranasal sinus X-rays on days 1 and 
14 (Table 1). The presence of colored nasal discharge on nasal 
endoscopy was assigned a score of 3 and 0 if absent. As for si-
nuses X-rays, presence of air fluid level or partial opacification 
was scored as 1 and 2 if total opacification. 
  On each visit, we evaluated symptom improvement, compli-
ance and adverse effects. All patients were instructed to visit the 
clinic on days 7, 14, and 28 after initial treatment. 
Determination of efficacy
Clinical response was classified as remission, improvement, same 
as before or aggravation. Remission was defined as resolution of 
symptoms of ARS and no requirement for additional antibiotics 
for the treatment of ARS. Improvement was considered to have 
Table 1. Study design  
Contents
Visit 1 Visit 2 Visit 3 Visit 4*
Pre-
therapy
On- 
therapy
Post- 
therapy
Late post-
therapy
Day 1
7 Days 
from day 1
Completed 
day of pre-
scribed  
treatment
28 Days 
from day 1
Informed consent O
History taking O
Physical examination O O O O
Symptoms and signs O O  O O
Monitoring of side effect O O O
Endoscopic exam O O O O
Paranasal sinuses X-ray O O
*Depending on the investigator’s decision for the need to revisit based on 
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occurred when all signs and symptoms of ARS present at enroll-
ment were decreased significantly. Same as before was defined 
when all signs and symptoms of ARS continued without change 
and aggravation was the status when all signs and symptoms 
were more deteriorating, thus required for additional antibiotics 
for the treatment. 
  At visit 3 (day 14), the overall clinical response was grouped 
as success (cases with remission or improvement) or failure (cas-
es with same as before or aggravation of symptoms). At visit 4 
(day 28), the clinical response was also defined as success (con-
tinued remission or improvement) or failure (same as before or 
reappearance of signs and symptoms and need for antibacterial 
therapy). Relapse was defined as the reappearance of clinical 
signs and symptoms at day 21 or 28 in a patient who showed 
improvement till day 14 and persistent infection was defined as 
sinus symptoms continuing at day 21 or 28 without experienc-
ing the improvement of symptoms. 
  The primary end point was determined based on the symp-
toms and endoscopic finding on the second and fourth week. 
The secondary end point was based on adverse reaction. 
Statistical analysis
Demographics and clinical characteristics of the study groups 
were compared using the Fisher exact test or the Mann-Whitney 
U test. The Fisher exact test was used to compare radiographic 
findings, adverse effects and the use of concomitant medications 
between groups. Differences in treatment duration and outcomes 
between groups were analyzed using the Mann-Whitney U test. 
Values were considered statistically significant if P<0.05. All anal-
yses were performed using SPSS ver. 12 (SPSS Inc., Chicago, IL, 
USA).
RESULTS
Demographics and clinical characteristics 
Of the 60 enrolled patients, 49 patients (81.7%) completed the 
trial. 5 patients in the CP group and 6 in the AMC group were 
excluded due to poor compliance, self discontinuation or adverse 
reactions. There was no significant difference regarding treatment 
compliance (83.3% vs. 80.0%).
  With the exception of history of allergic rhinitis, the two 
groups did not show any difference in terms of sex, age, number 
of days with rhinosinusitis-related symptoms, pre-treatment du-
ration, prescribed medications before enrollment, initial radio-
graphic findings and clinical findings for purulent discharge from 
the ostiomeatal unit from endoscopic findings, initial symptoms, 
and the additional use of concomitant medication (Table 2). 
  The most common symptoms in both groups were nasal dis-
charge/postnasal drip (100% in both groups), nasal obstruction 
(96% vs. 86%), cough (64% vs. 75%), and hyposmia (72% vs. 
58%).
  The most common findings on sinus radiographs taken during 
the first visit were ‘air-fluid level or partial opacification’ in both 
groups and there were no statistically significant differences in 
the initial radiographic findings between the two groups. Six pa-
tients from the CP group and 1 patient from the AMC group used 
concomitant medications which included mucolytics, antihista-
mines, oral decongestants or intranasal corticosteroid sprays.
Therapeutic outcomes
On their second visit (day 7), complete remission of symptoms 
or partial improvement of symptoms was seen in 96.0% and 
100.0% of patients in the CP and AMC groups, respectively; on 
the third visit (day 14), 96.0% and 95.8% of the patients in each 
group showed improvement; and on the fourth visit (day 28), 
100% and 95.9% showed improvement compared to pretreat-
ment. The change of symptom scores was statistically significant 
on days 7, 14, and 28 in both groups (P<0.001), however there 
was no difference between the two groups in any visit period. 
Relapse was seen in 1 patient in the AMC group (Table 3). 
  The most common findings on sinus radiographs taken during 
the third visit were ‘not significant’ in both groups and most of 
the patients having diffuse opacification on X-ray initially showed 
improvement on follow up X-ray. 
Adverse reactions 
The most commonly reported adverse event in the CP and AMC 
groups was GI trouble, especially diarrhea (4.0% vs. 25.0%, re-
spectively; P=0.04) (Table 4). Other adverse reactions included 
insomnia, rash and itching in the CP group and epigastric pain, 
constipation and rash in the AMC group. No major side effects 
were identified during the study. 
Table 2. Demographic and clinical characteristics of patients
Cefcapene 
pivoxil
Amoxicillin-
clavulanate
P-value
Sex, no (%) 0.55
   Male 10 (40)   7 (29.1)
   Female 15 (60) 17 (70.8)
Age, median 48.8 46.7 0.79
Medical history 
   Allergic rhinitis 6 0 0.02
   Asthma  2 0 0.49
Pre-treatment 9 4 0.19
Radiographic findings (visit 1) 0.06
   Not significant  0 0
   Air-fluid level or partial opacification  14 18
   Diffuse opacification  11 6
Endoscopy exam (visit 1) 0.75
   Absence of purulent discharge 2 2
   Mild    7 10
   Moderate 14 10
   Severe  2 286    Clinical and Experimental Otorhinolaryngology   Vol. 4, No. 2: 83-87 , June 2011
DISCUSSION
Extended-spectrum cephalosporins (e.g., cefuroxime azetil, cef-
podoxime prozetil, and cefdinir) have been demonstrated to be 
effective against organisms isolated in ARS (Streptococcus pneu-
monia, Haemophilus influenza, and Moraxella catarrhalis) (1, 2).
  The reasons why we compared the efficacy of AMC to CP is 
that the key offending organism is commonly amoxicillin-resis-
tant (5). In our randomized, double-blinded, open label trial, we 
aimed to compare the efficacy of CP and AMC in the treatment 
of ARS. 
  Our results regarding frequent nasal symptoms were similar 
with those of Tantimongkolsuk et al. (6), although it was perform-
ed in children with rhinosinusitis, in which rhinorrhea (95.0%), 
cough (91.0%), and nasal blockage (74.0%) were the most fre-
quent presenting symptoms. A study regarding the signs and 
symptoms of ARS suggested that patient-reported symptoms 
such as a previous common cold or facial pain do not help to 
distinguish a bacterial infection from a viral infection, thus it 
could not be a reliable marker to warrant the prescription of an-
tibiotics. Moreover, they have reported the presence of purulent 
nasal discharge is also insufficient to justify antibiotic treatment 
(4, 7). Thus, in our study, the diagnosis of ARS was based on clin-
ical symptoms and signs together with radiographic imaging. 
  Most of the patients in both groups were improved with 
2-week antibiotic medication and there was no statistical signifi-
cance in improvement rate between groups (P=0.88). One pa-
tient in AMC group showed improvement at the day 7 and 14 
day follow-ups, after which his symptoms became aggravated at 
the day 28 follow-up. Interpreting clinical efficacy demands cau-
tion because distinguishing patients with relapse from those with 
persistent infection can be difficult. In this case, being catego-
rized as ‘relapse’ seems to be justified based on the fact that hav-
ing taken improvement period before aggravation of symptom.
  According to previous published guideline on ARS, radiograph-
ic imaging is not routinely recommended in patients who meet 
the diagnostic criteria for acute rhinosinusitis (8). This is because 
clinical criteria itself has comparable accuracy to sinus radiogra-
phy, and therefore radiographs are reserved to patients with co-
morbidities that predisposes them to complications including di-
abetes, immune compromised state, or past history of facial trau-
ma. 
  It is well known that the time needed for outstanding changes 
to occur in plain film is likely to be much longer than the time 
of symptomatic improvement. Therefore, following up the pa-
tient with plain sinus films, although certainly less costly, do have 
limitations and are generally less reliable than CT or MR images. 
Nevertheless, it might be adequate for an ARS study in terms of 
confirmation of the diagnosis with definite air fluid level and par-
tial or diffuse opacification, detection of any abnormality locat-
ed in paranasal sinuses roughly, comparability of the films taken 
during different time. 
  The most common finding present in the paranasal sinus ra-
diographs performed on the first visit was ‘air-fluid level’ or ‘par-
tial opacification’ in both CP and AMC groups (56% vs. 58.3%, 
CP vs. AMC). However, 2 weeks later, the most common radio-
graphic finding was ‘not significant’ in both groups (40% in CP 
group and 41.7% in AMC group). While 44% of patients in the 
CP and 25% of the AMC group showed diffuse opacification on 
radiography on the first visit (day 1), only 16% and 4% of pa-
tients showed diffuse opacification on the third visit (day 14). 
There were no significant differences in terms of radiographic 
findings between the two groups at any given time point. Among 
the 11 patients with diffuse opacification on X-rays taken during 
visit 1 in the CP group, a total of 7 patients showed radiological 
improvement as ‘partial opacification’ or ‘not significant,’ and 
those were combined with clinical improvement. In the AMC 
group, all 6 patients having diffuse opacification showed improve-
ment to normal or partial opacification. While improvement of 
Table 3. Treatment outcomes 
Parameter
Cefcapene 
pivoxil (n=25)
Amoxicillin-cla-
vulanate (n=24)
P-value
Treatment duration, day 14.0 14.0 1.00
Change in symptom score (mean)
   Day 7-0   4.20   3.79 0.23
   Day 14-7   1.60   1.83 0.41
   Day 28-14   1.52   1.58 0.44
Clinical improvement* (%)
   Day 7  24 (96.0) 24 (100) 0.32
   Day 14  24 (96.0) 23 (95.8) 0.32
   Day 28 25 (100) 23 (95.8) 0.31
   Relapse
†    0 (0.00)   1 (0.04) 0.88
Radiographic findings (visit 3) 0.41
   Not significant  10 10
   A  ir-fluid level or partial opaci-
fication 
  9 10
   Diffuse opacification    4   1
Endoscopy exam (visit 3) 0.44
   Absence of purulent discharge 14 16
   Mild      8   5
   Moderate   3   3
   Severe    0   0
*Patients who showed complete remission or partial improvement; 
†Pati-
ents who showed improvement during the 1, 2 week follow-up, but showed 
aggravation in the last follow-up. 
Table 4. Frequency of adverse reactions reported during the treat-
ment period
Cefcapene  
pivoxil
Amoxicillin-
clavulanate
P-value
Gastrointestinal trouble 1 6 0.04
Insomnia 1 0 0.58
Skin rash 1 1 0.75
Total 3 7 0.17Lee J-E et al.: Efficacy and Safety of Cefcapene Pivoxil and Amoxicillin-Clavulanate in Acute Rhinosinusitis    87
X-ray findings was accompanied by decreased symptoms and 
signs of ARS in 4 patients, 2 patients failed to go together.
  By chance, all patients who had asthma or allergic rhinitis were 
assigned to one group. Patients used symptomatic medication, 6 
patients in CP group and 1 patient in AMC group, which would 
affect clinical outcomes. Therefore, whether asthma or allergic 
rhinitis can influence the recovery from ARS could not be evalu-
ated exactly in this study. Even though it is true, since these pa-
tients was on the CP treated group in present study, the similar 
therapeutic results of both drugs suggest that the effectiveness of 
CP is not inferior to that of the AMC as the first line recommen-
ded drug in treatment of ARS.
  The most common adverse effect that occurred in this study 
was GI trouble including diarrhea, epigastric soreness and con-
stipation. A common side effect of antibiotics is diarrhea, which 
may be caused by the elimination of beneficial bacteria normal-
ly found in colon. According to the previous studies, the frequen-
cy of diarrhea of patients treated with AMC was reported from 
10.9% to 21.0% (9-12). Patients treated with different kind of 
cephalosporin had a lower rate of adverse clinical events com-
pared to those with amoxicillin-clavulanate (3, 13). In present 
study, the incidence of diarrhea during treatment with AMC, al-
though it was numerically lower than the previous report, was 
higher than that with CP. 
  The limitations of this study include absence of bacteriologic 
study and small sample size recruited from a single hospital may 
limit the generalization of the finding. Bacterial cultures are str-
ongly recommended for studies of antibiotic treatment and pro-
vide valuable information for any therapeutic trial of ARS, how-
ever, there are limitations of bacterial culture that prevent the 
routine use for antibiotic trials. There is a difficulty in getting the 
patients to agree with the invasive procedure and many culture 
methods such as blind nasal swab, nasopharyngeal swab, endo-
scopically directed cultures of the middle meatus and maxillary 
sinus tapping have been evaluated and debated whether that 
method is promising or not to identify the pathogens (14). 
  This study provides evidence suggesting that CP is as effective 
as AMC for the treatment of ARS in adults in terms of symptom 
improvement and relapse. In addition, CP treatment showed su-
periority to AMC in terms of GI adverse effects. 
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES
1. Anon JB, Jacobs MR, Poole MD, Ambrose PG, Benninger MS, Had-
ley JA, et al. Antimicrobial treatment guidelines for acute bacterial 
rhinosinusitis. Otolaryngol Head Neck Surg. 2004 Jan;130(1 Sup-
pl):1-45. 
2. Wald ER. Microbiology of acute and chronic sinusitis in children. J 
Allergy Clin Immunol. 1992 Sep;90(3 Pt 2):452-6. 
3. Sakata H. Comparative study of 5-day cefcapene-pivoxil and 10-day 
amoxicillin or cefcapene-pivoxil for treatment of group A strepto-
coccal pharyngitis in children. J Infect Chemother. 2008 Jun;14(3): 
208-12. 
4. Lanza DC, Kennedy DW. Adult rhinosinusitis defined. Otolaryngol 
Head Neck Surg. 1997 Sep;117(3 Pt 2):S1-7. 
5. Anon JB, Berkowitz E, Breton J, Twynholm M. Efficacy/safety of amo-
xicillin/clavulanate in adults with bacterial rhinosinusitis. Am J Oto-
laryngol. 2006 Jul-Aug;27(4):248-54. 
6. Tantimongkolsuk C, Pornrattanarungsee S, Chiewvit P, Visitsunthorn 
N, Ungkanont K, Vichyanond P. Pediatric sinusitis:symptom profiles 
with associated atopic conditions. J Med Assoc Thai. 2005 Nov;88 
Suppl 8:S149-55. 
7. Young J, De Sutter A, Merenstein D, van Essen GA, Kaiser L, Varo-
nen H, et al. Antibiotics for adults with clinically diagnosed acute rhi-
nosinusitis: a meta-analysis of individual patient data. Lancet. 2008 
Mar 15;371(9616):908-14.
8. Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, 
Ganiats TG, et al. Clinical practice guideline: adult sinusitis. Otolar-
yngol Head Neck Surg. 2007 Sep;137(3 Suppl):S1-31. 
9. Garbutt JM, Goldstein M, Gellman E, Shannon W, Littenberg B. A 
randomized, placebo-controlled trial of antimicrobial treatment for 
children with clinically diagnosed acute sinusitis. Pediatrics. 2001 
Apr;107(4):619-25. 
10. Bottenfield GW, Burch DJ, Hedrick JA, Schaten R, Rowinski CA, Da-
vies JT. Safety and tolerability of a new formulation (90 mg/kg/day 
divided every 12 h) of amoxicillin/clavulanate (Augmentin) in the 
empiric treatment of pediatric acute otitis media caused by drug-re-
sistant Streptococcus pneumoniae. Pediatr Infect Dis J. 1998 Oct; 
17(10):963-8. 
11. Poachanukoon O, Kitcharoensakkul M. Efficacy of cefditoren pivoxil 
and amoxicillin/clavulanate in the treatment of pediatric patients with 
acute bacterial rhinosinusitis in Thailand: a randomized, investigator-
blinded, controlled trial. Clin Ther. 2008 Oct;30(10):1870-9. 
12. Kafetzis DA. Multi-investigator evaluation of the efficacy and safety 
of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the 
treatment of acute otitis media. Eur J Clin Microbiol Infect Dis. 1994 
Oct;13(10):857-65.
13. Henry DC, Kapral D, Busman TA, Paris MM. Cefdinir versus levo-
floxacin in patients with acute rhinosinusitis of presumed bacterial 
etiology: a multicenter, randomized, double-blind study. Clin Ther. 
2004 Dec;26(12):2026-33. 
14. Benninger MS, Payne SC, Ferguson BJ, Hadley JA, Ahmad N. Endo-
scopically directed middle meatal cultures versus maxillary sinus taps 
in acute bacterial maxillary rhinosinusitis: a meta-analysis. Otolar-
yngol Head Neck Surg. 2006 Jan;134(1):3-9. 